2003•New England Journal of MedicineRequires access
Aromatase Inhibitors in Breast Cancer
Ian E. Smith, Mitch Dowsett
Open publisher page 906 citations
Abstract
Until recently, tamoxifen, a nonsteroidal antiestrogen, was the mainstay of endocrine treatment of breast cancer. However, new aromatase inhibitors that are many times more potent and specific than the first such agent, aminoglutethimide, are changing the management of breast cancer in postmenopausal women. This review discusses the role of aromatase inhibitors such as letrozole, anastrozole, and exemestane in the treatment of breast cancer.